MedPath

Neurofeedback Therapy for Children Diagnosed With Autism

Not Applicable
Completed
Conditions
Autism Spectrum Disorder
Interventions
Device: Mente Autism™
Device: Sham
Registration Number
NCT02773303
Lead Sponsor
Carrick Institute for Graduate Studies
Brief Summary

This project aims:

* to further explore the effectiveness of a novel sonified Neurofeedback management therapy for children diagnosed with Autism Spectrum Disorder (ASD)

* to determine if balance control is different before and after therapy

Detailed Description

Once the informed consent of a parent or guardian has been secured, each child will be asked to provide informed assent. If the child elects to participate in the research project, he/she is enrolled in the study and assign to one of two groups: Active Comparator or Sham Comparator. If possible, his/her ability to maintain balance is then assessed using a standard extended mCTSIB protocol (standing for 25 seconds on a hard surface/4" tall foam cushion with eyes open/closed and head neutral/turned right/left/flexed or extended) and his/her baseline qEEG are recorded. A series of questionnaires will be administered to the child and/or his/her parents/legal guardian/caretaker.

Afterward the child will be instructed to wear the prescribed device (either the Active Comparator (Mente Autism™) or the Sham Comparator (a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats)) to use at home for 40 minutes a day for 12 weeks. At the end of the 12 weeks treatment period, the child will again be tested as at the beginning of the trial (posturography, qEEG, and questionnaires). At the end of the study, participants in the Sham Comparator group will be offered the option of receiving the full therapy.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
83
Inclusion Criteria
  • a clear diagnosis of ASD and a high starting delta wave level, as confirmed by the initial qEEG.

Furthermore, since the therapy is administered via a device requiring to be connected to a computer, tablet or phone with WiFi capabilities to work, the following are additional requirement:

  • iPhone 4s or later or all iPads except first generation iPAD running OS v7 or later, or
  • computer running Windows 7 or later
  • Tablet running Android 4.1 or later
  • Internet connection
Exclusion Criteria
  • a history of hearing impairment and co-morbidities such as Rett-Syndrome and if they get low delta wave recordings in frontal lobe with qEEG (part of the baseline testing battery)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ActiveMente Autism™Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
ControlShamChildren not receiving neurofeedback based therapy, but receiving the Sham therapy
Primary Outcome Measures
NameTimeMethod
Changes in qEEGBaseline and at week 12

Changes will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.

Secondary Outcome Measures
NameTimeMethod
Changes in Stability ScoreBaseline and at week 12

The Stability Score is calculated as percentage ratio of the actual sway and the theoretical limit of stability.

Changes in Stability Score will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.

Changes in Social Responsiveness Scale (Second Edition) SRS-2Baseline and at week 12

Changes will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.

Changes in Autism Behaviour Checklist (ABC)Baseline and at week 12

Changes will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.

The Behavior Rating Inventory of Executive Function (BRIEF)Baseline and at week 12

Changes will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.

Changes in Questions about Behavioural Function (QABF) testBaseline and at week 12

Changes will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.

Trial Locations

Locations (1)

Plasticity Brain Centers

🇺🇸

Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath